Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigatuzumab + Chemo in Advanced NSCLC
NCT00991796Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2009
- Primary completion
- Jul 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tigatuzumab in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Jun 2009; status: completed.
02
Drugs
tigatuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00991796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00991796.